A Flagship VentureLabs Company

Eleven Biotherapeutics, Inc.

215 First Street
Suite 400

Cambridge, MA  02142

Tel: 617.871.9911


Leadership:
Abbie Celniker, PhD
CEO


Website:
www.elevenbio.com

Eleven Biotherapeutics, Inc.

Flagship Partners:  Noubar Afeyan, David Berry
Initial Investment: 
2008
Status: 
Public

Eleven Biotherapeutics (NASDAQ: EBIO) is a publicly traded clinical-stage biopharmaceutical company with a proprietary protein engineering platform, called AMP-Rx, that it applies to the discovery and development of protein therapeutics to treat diseases of the eye. The company’s therapeutic approach is based on the role of cytokines in diseases of the eye, the company’s understanding of the structural biology of cytokines and the company’s ability to rationally design and engineer proteins to modulate the effects of cytokines. Cytokines are cell signaling molecules found in the body that can have important inflammatory effects. 

Noubar Afeyan and David Berry are on the Board of Directors.